Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18311614 | 0.95 | GRM2 (0.56) | GRM2SLC9A1TLR8MPO | |
| SCHEMBL24134933 | 0.84 | SLC9A1 (0.44) | GRM2SLC9A1 | |
| SCHEMBL18070761 | 0.82 | GRM2 (0.51) | GRM2SLC9A1 | |
| SCHEMBL309237 | 0.82 | TLR8 (0.50) | SLC9A1TLR8 | |
| SCHEMBL13641426 | 0.81 | PKM (0.41) | GRM2SLC9A1CNR2CNR1PKM | |
| SCHEMBL20608120 | 0.80 | TDO2 (0.40) | GRM2 | |
| SCHEMBL29561346 | 0.80 | TDO2 (0.40) | GRM2 | |
| SCHEMBL13332354 | 0.78 | SLC9A1 (0.41) | GRM2SLC9A1CNR2PKMTLR8 | |
| SCHEMBL476964 | 0.77 | CNR1 (0.46) | SLC9A1CNR2CNR1PKM | |
| SCHEMBL4086740 | 0.76 | CNR2 (0.49) | SLC9A1CNR2CNR1PKMMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | claimed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | claimed |
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20100016331-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2086942-A2 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009074590-A1 | N- (2 { [1-PHENYL-1H-INDAZ0L-4-YL] AMINO} PROPYL) -SULFONAMIDE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| WO-2009050220-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-2013185-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008043788-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-1869003-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, MC2R | GRM2 211/4885SLC9A1 816/4885CNR2 255/4885 |
| US-20070265326-A1 | NOVEL COMPOUNDS | CCL11, MRGPRX2, LTB4R2 | GRM2 2257/4885SLC9A1 3477/4885CNR2 77/4885 |
| US-20090111866-A1 | Novel Compounds | CCL11, MRGPRX2, LTB4R2 | GRM2 2257/4885SLC9A1 3477/4885CNR2 77/4885 |
| US-20100016331-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | GRM2 4151/4885SLC9A1 3873/4885CNR2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.